Chen Wan-Shan 4

What Happened Chen Wan-Shan, a director of Belite Bio, had a previously granted, performance-based stock option vest as to 13,796 ordinary shares on March 31, 2026. The filing reports an acquisition of 13,796 shares at $0.00 (derivative award); this was not an open-market purchase or sale and no cash was paid at vesting.

Key Details

• Transaction date: 2026-03-31; Report filed: 2026-04-02 (filed two business days after the transaction).
• Shares acquired: 13,796 ordinary shares; reported price: $0.00 (derivative/award).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The option was originally granted on 12/23/2020 and vests upon satisfaction of performance criteria. One performance criterion was met on 3/31/2026, triggering vesting of these 13,796 shares. The filing notes that all previously vested shares under the option had already been exercised.
• Filing appears timely (within the Form 4 reporting window).

Context This was a performance-based option vesting (an award), not a market purchase or sale. Awards and vesting are common executive compensation events and do not by themselves indicate buying or selling sentiment. No immediate sale or cashless exercise of these newly vested shares is reported in the provided filing.